作者:Ariamala Gopalsamy、Mengxiao Shi、Yongbo Hu、Frederick Lee、Larry Feldberg、Eileen Frommer、Steven Kim、Karen Collins、Donald Wojciechowicz、Robert Mallon
DOI:10.1016/j.bmcl.2010.03.030
日期:2010.4
In continuation of our efforts toward hit identification and optimization for a B-Raf kinase project, we have employed a scaffold hopping strategy. The original HTS hit scaffold pyrazolo[1,5-a]pyrimidine was replaced with different thienopyrimidine and thienopyridine scaffolds to append the optimal pharmacophore moieties in order to generate novel B-raf kinase inhibitors with desirable potency and properties
为了继续努力进行B-Raf激酶项目的命中识别和优化,我们采用了支架跳跃策略。最初的HTS命中支架吡唑并[1,5- a ]嘧啶被不同的噻吩并嘧啶和噻吩并吡啶支架取代,以附加最佳药效团部分,以产生具有所需效价和特性的新型B-raf激酶抑制剂。该策略导致鉴定具有良好的酶和细胞效力,同时保持对多种激酶的选择性的另外的前导化合物11b。